Diabetes is a disease with a rapid increase worldwide and a typical chronic disease that causes serious complications.
Because there are no early symptoms of diabetes complications in general, early diagnosis becomes more critical.
Especially since the early 1990s, many studies have showed a high correlation between diabetic vascular disease and rheological factors of blood.
According to the rising demands, the Korean company specialized in manufacturing diagnostic kits for blood tests has developed the world`s first system that can measure hemorheological indices on sites, using disposable test kits that enabled early diagnosis before simple diabetes transitioning to diabetes complications. The company’s products have been successfully certified for standards such as CE and ISO13485, and achieved approval of items by KFDA(Korean Food and Drug Administration). The products have been launched in both domestic and international markets, and being used as diagnostic hemorheological markers for diabetic microvascular complications.
The devices were designed to measure three different hematopoietic indices- RBC(red blood cell) deformability, RBC(red blood cell) aggregation and CSS(critical shear stress)- in one device. Being made of microchip for the purpose of convenient/easy clinical use would be one of the main features of this device.
Combining with advanced microfluidic and optical technologies that provide superior repeatability and accuracy, this device is proudly used by renowned research institutions such as the US FDA(Food and Drug Administration) and NIH(National Institutes of Health).
While the RBC(red blood cell) deformation is a hemodynamic factor that decreases sensitively as diabetes progresses, CSS(critical shear stress) can also be considered as a useful indicator for early diagnosis of diabetic microvascular complications.
The efficiency of using the company’s products for early diagnosis has already been proved by some of the clinical studies conducted by renown hospitals in Korea- the hemodynamic properties of RBCs(red blood cell) from each with healthy people and ones with diabetics were examined and compared using the devices.
The company has experience working with European partners, however, seeking additional business partners to expand its market in Europe under distribution services agreement.